Kymera Therapeutics KYMR 深 滬
已收盤 09-25 16:00:00 美东时间
111.95
-3.860
-3.33%
華盛通- 最 高116.20
- 今 開115.99
- 成交量 69.84万股
- 最 低 111.42
- 昨 收 115.81
- 總市值 93.09亿
- 52周最高 130.05
- 市盈率 靜 --
- 換手率 0.84%
- 52周最低 55.2601
- 委 比 -47.52%
- 總股本 8315.06万
- 歷史最高 130.05
- 量 比 0.68
- 振 幅 4.13%
- 歷史最低 9.60
- 每 手 1
- 風險率 19.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152
Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.
09-22 18:43
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.
09-15 01:47
Wolfe Research Upgrades Kymera Therapeutics to Outperform
Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform.
09-10 21:36
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor events, including the Wells Fargo Healthcare Conference, Citi Biopharma Summit, H.C. Wainwright Global Investment Conference, Morgan Stanley Global Healthcare Conference, and Stifel Immunology Forum. Live webcasts and replays will be available on the company’s website. Kymera focuses on developing oral small molecule degraders...
09-02 20:01
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
美股大行评级 | 潜在涨幅1024.26%！Ascendiant Capital上调PAVmed目标价至57美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从56美元升至57美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9.25美元升至9.5美元
08-28 16:15
The Trend Catcher | Comml Svcs-Staffing Continues to Strengthen, YYGH Surges 68%; EXEL, MCO, MNST (Rating 95+) Nearing Breakouts
Markets were flat as PCE inflation matched core expectations, while Machinery and Staffing sectors led gains, and Cre8, Expion360, and YY Group posted sharp rallies.
08-26 23:00
